VentriFlo® has been identified as one of the top emerging MedTech startup companies in 2019 by the international MedTech Innovator competition. Out of more than 750 applicants, only the most promising 150 companies have been chosen to advance to the next level. VentriFlo is honored to have been selected as one of the companies, and will participate in the next-level qualifying event being held in Minneapolis, Minnesota, on March 27th, 2019.
Paul Grand, CEO of MedTech Innovator says in a recent article in LinkedIn’s Pulse, ”Our cohorts of Accelerator & Showcase companies undergo a rigorous narrowing process and are carefully selected from the best and brightest around the globe. These entrepreneurs are working tirelessly to address unmet medical needs, reduce the cost of care, ease the burden on physicians and care teams, and make life better for a significant number of people.”
As stated on MedTech Innovator’s website, “MedTech Innovator evaluates applicants along three different [axes] that help to identify the improved value to patient care and transformative potential: Value, Momentum, Execution.”
VentriFlo, a patented blood pump technology currently in development by Design Mentor, of Pelham, NH, recently won 2nd place in the NH Tech Alliance’s TechOut2018 Competition, and was also an award winner of the Children’s National Health System’s Pediatric Device Innovation Competition.
VentriFlo marks a revolutionary advancement over current blood pumps. Unlike the human heart, current blood pump technology uses continuous pressure to circulate blood. VentriFlo revolutionizes circulatory technology by delivering a life-like pulse to a patient during heart surgery and during post-surgical support when their own heart is unable to provide a native pulse.
With an experienced management and development team, and a world-renown list of Scientific Advisors, VentriFlo is well positioned to positively disrupt Heart-Lung medtech options. VentriFlo is poised to improve patient outcomes during surgery and in the years following, while decreasing the costs to hospitals, insurance companies and patients that are associated with longer hospital stays, readmissions and complications.